Managing Psychiatric Medications in CYP2D6 Poor Metabolizers

Medication-Specific Dosing Adjustments

The American College of Physicians and other medical societies recommend that for patients taking fluoxetine, a single-dose of 20 mg produces a 3.9-fold higher AUC in poor metabolizers versus extensive metabolizers, and at 60 mg, the increase is 11.5-fold for S-fluoxetine, indicating a need for dose adjustment 1
Paroxetine shows similar patterns, with a 30 mg single dose producing a 7-fold higher AUC in poor metabolizers versus extensive metabolizers, though this decreases to 1.7-fold with chronic dosing due to enzyme saturation, as reported by the Mayo Clinic Proceedings 1
The FDA has issued warnings that fluoxetine should be used with caution in CYP2D6 poor metabolizers due to QT prolongation risk and potential for sudden cardiac death, as documented in the medical literature 1
For patients taking venlafaxine, poor metabolizers show dramatically altered O-desmethylvenlafaxine to venlafaxine ratios, and starting at 50% of standard dose is recommended, given the substantial accumulation of parent compound in poor metabolizers, according to the Mayo Clinic Proceedings 1
For patients taking atomoxetine, poor metabolizers comprise 5-8% of Caucasian populations, and reducing the dose by 50% in known poor metabolizers prevents accumulation to toxic levels, as recommended by medical guidelines 2

Fluoxetine converts 43% of extensive metabolizers to poor metabolizers, at 20 mg/day chronic dosing, fluoxetine acts as a potent CYP2D6 inhibitor, creating "phenocopy" poor metabolizer status, as reported in the Mayo Clinic Proceedings 1
There is a documented fatalities due to cardiac arrest with venlafaxine blood concentration of 4.5 mg/kg, attributed to CYP2D6 poor metabolizer phenotype, highlighting the importance of careful dose adjustment and monitoring 1
Poor metabolizers are at increased risk for cardiac arrhythmias, particularly with fluoxetine and other QT-prolonging agents, and serotonin syndrome risk is also elevated, as documented in the medical literature 1

Genetic testing is recommended before starting medications with narrow therapeutic indices, particularly tricyclic antidepressants, atomoxetine, and certain antipsychotics, as suggested by medical guidelines 3
The EGAPP Working Group found insufficient evidence for routine CYP450 testing in all patients starting SSRIs for nonpsychotic depression, and therapeutic drug monitoring offers a practical alternative to genetic testing by capturing both genetic and acquired poor metabolizer phenotypes, as reported in Genetics in Medicine [4] [5]

The American College of Cardiology recommends reducing the starting dose by 50% for most CYP2D6-substrate drugs, particularly SSRIs like fluoxetine and paroxetine, SNRIs like venlafaxine, and atomoxetine, due to dramatically elevated drug concentrations that increase risks of cardiac arrhythmias, QT prolongation, serotonin syndrome, and sudden death in CYP2D6 poor metabolizers 6
The FDA specifically warns that fluoxetine should be used with caution in CYP2D6 poor metabolizers due to QT prolongation risk and potential sudden cardiac death 6
Aripiprazole requires dose reduction in poor metabolizers of CYP2D6, as recommended by the European Society of Cardiology 7

Fluoxetine, paroxetine, and venlafaxine all carry increased risk of QT prolongation and cardiac arrhythmias in poor metabolizers, according to the American Heart Association 6
The FDA mandates caution with fluoxetine in patients with congenital long QT syndrome, family history of sudden cardiac death, or CYP2D6 poor metabolizer status 6
Avoid combining QT-prolonging agents in poor metabolizers whenever possible, as recommended by the European Society of Cardiology 7

Obtain baseline ECG before initiating CYP2D6-substrate medications in known poor metabolizers, as recommended by the American College of Cardiology 6

Use extreme caution with high-dose SSRIs in children, and strongly consider genetic testing before exceeding standard pediatric doses, as recommended by the American Academy of Pediatrics 6
Genetic testing or therapeutic drug monitoring is strongly recommended before escalating to high-dose SSRI therapy, according to the National Institute of Mental Health 6

The American College of Medical Genetics recommends using standardized PharmVar nomenclature with the multiplication sign and number of gene copies for duplications to state the specific star allele combination detected, such as CYP2D61/4 or CYP2D62×2/4 8
The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines suggest that patients can be classified as Poor Metabolizers (PM), Intermediate Metabolizers (IM), Extensive/Normal Metabolizers (EM), or Ultrarapid Metabolizers (UM) based on their CYP2D6 diplotype, with PMs having little to no enzyme activity and UMs having increased activity 9, 10
Comprehensive CYP2D6 testing should include single nucleotide polymorphisms (SNVs), copy number variants (CNVs), and structural variants, such as gene deletions, duplications, and multiplications, to accurately determine the patient's metabolizer phenotype 8, 11

The CPIC guidelines recommend providing specific dosing guidance for medications affected by CYP2D6, such as fluoxetine, paroxetine, and venlafaxine, based on the patient's metabolizer phenotype 12
Approximately 20-25% of all clinically used drugs are metabolized by CYP2D6, including many psychiatric medications, pain medications, and cardiovascular drugs, highlighting the importance of considering CYP2D6 pharmacogenetics in clinical decision-making 12

The Mayo Clinic recommends monitoring patients for signs of drug accumulation or treatment failure based on their CYP2D6 metabolizer phenotype, with therapeutic drug monitoring (TDM) and baseline ECG recommended for poor metabolizers and ultrarapid metabolizers on certain medications 9, 10
Genetic counseling services may be available to answer patient questions about their CYP2D6 test results and implications for medication use 12
Laboratory contact information should be provided for technical questions about the test methodology, and a copy of the official laboratory report with full diplotype and phenotype interpretation should be attached to the patient's records 8, 11